Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC lifted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 19.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,061 shares of the medical instruments supplier's stock after purchasing an additional 9,101 shares during the period. Intech Investment Management LLC's holdings in Becton, Dickinson and Company were worth $12,492,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of BDX. Generali Asset Management SPA SGR acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $2,626,000. Horizon Investments LLC raised its position in Becton, Dickinson and Company by 9.5% during the fourth quarter. Horizon Investments LLC now owns 15,263 shares of the medical instruments supplier's stock worth $3,463,000 after acquiring an additional 1,323 shares during the period. Thrivent Financial for Lutherans raised its position in Becton, Dickinson and Company by 6.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 13,903 shares of the medical instruments supplier's stock worth $3,167,000 after acquiring an additional 808 shares during the period. Retirement Planning Co of New England Inc. grew its position in shares of Becton, Dickinson and Company by 49.6% in the fourth quarter. Retirement Planning Co of New England Inc. now owns 1,506 shares of the medical instruments supplier's stock valued at $342,000 after purchasing an additional 499 shares during the period. Finally, RD Lewis Holdings Inc. purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth about $416,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Remove Ads

Insiders Place Their Bets

In related news, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares in the company, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Richard Byrd sold 459 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total value of $105,570.00. Following the transaction, the executive vice president now owns 6,952 shares in the company, valued at $1,598,960. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,984 shares of company stock valued at $1,147,865 over the last quarter. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Trading Down 0.5 %

Becton, Dickinson and Company stock traded down $1.22 during trading on Friday, reaching $230.63. 4,372,181 shares of the company were exchanged, compared to its average volume of 1,539,966. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The stock's 50 day simple moving average is $232.64 and its two-hundred day simple moving average is $232.12. The company has a market capitalization of $66.22 billion, a P/E ratio of 38.31, a PEG ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has initiated a stock buyback plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.80%. Becton, Dickinson and Company's payout ratio is 69.10%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Barclays lifted their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, March 5th. Finally, Piper Sandler boosted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 28th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of "Buy" and a consensus target price of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.